Glucosylceramide synthase regulates adipo‐osteogenic differentiation through synergistic activation of PPARγ with GlcCer. Issue 1 (29th November 2019)

• Record Type: Journal Article
• Authors: Jang, Hyun‐Jun; Lim, Seyoung; Kim, Jung‐Min; Yoon, Sora; Lee, Chae Young; Hwang, Hyeon‐Jeong; Shin, Jeong Woo; Shin, Kyeong Jin; Kim, Hye Yun; Park, Kwang Il; Nam, Dougu; Lee, Ja Yil; Yea, Kyungmoo; Hirabayashi, Yoshio; Lee, Yu Jin; Chae, Young Chan; Suh, Pann‐Ghill; Choi, Jang Hyun
• Is Part Of: FASEB journal. Volume 34:Issue 1(2020)
• Page Start: 1270
• Page End: 1287
• Publication Date: 2019-11-29
• Subjects: adipogenesis -- glucosylceramide -- glucosylceramide synthase -- mesenchymal stem cells -- osteogenesis -- PDMP -- peroxisome proliferator‐activated receptor γ; Biology -- Periodicals; Biology, Experimental -- Periodicals; 570
• DOI: 10.1096/fj.201901437R
• Languages: English
• ISSNs: 0892-6638

Abstract

Abstract: Dysregulation of the adipo‐osteogenic differentiation balance of mesenchymal stem cells (MSCs), which are common progenitor cells of adipocytes and osteoblasts, has been associated with many pathophysiologic diseases, such as obesity, osteopenia, and osteoporosis. Growing evidence suggests that lipid metabolism is crucial for maintaining stem cell homeostasis and cell differentiation; however, the detailed underlying mechanisms are largely unknown. Here, we demonstrate that glucosylceramide (GlcCer) and its synthase, glucosylceramide synthase (GCS), are key determinants of MSC differentiation into adipocytes or osteoblasts. GCS expression was increased during adipogenesis and decreased during osteogenesis. Targeting GCS using RNA interference or a chemical inhibitor enhanced osteogenesis and inhibited adipogenesis by controlling the transcriptional activity of peroxisome proliferator‐activated receptor γ (PPARγ). Treatment with GlcCer sufficiently rescued adipogenesis and inhibited osteogenesis in GCS knockdown MSCs. Mechanistically, GlcCer interacted directly with PPARγ through A/B domain and synergistically enhanced rosiglitazone‐induced PPARγ activation without changing PPARγ expression, thereby treatment with exogenous GlcCer increased adipogenesis and inhibited osteogenesis. Animal studies demonstrated that inhibiting GCS reduced adipocyte formation in white adipose tissues under normal chow diet and high‐fat diet feeding and accelerated bone repair in a calvarial defect model. Taken together, our findings identify a novel lipid metabolic regulator for the control of MSC differentiation and may have important therapeutic implications.